QLS-101ophthalmic solution 1% ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 157 | Sturge-Weber syndrome | 1 |
157. Sturge-Weber syndrome
Clinical trials : 10 / Drugs : 14 - (DrugBank : 4) / Drug target genes : 5 - Drug target pathways : 63
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04947124 (ClinicalTrials.gov) | October 19, 2021 | 8/6/2021 | A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 | Masked, Randomized, Single-site, Crossover Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 Dosed for 14 Days in Adult Subjects With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP) | Sturge-Weber Syndrome (SWS);Glaucoma;Glaucoma Congenital;Ocular Hypertension | Drug: QLS-101ophthalmic solution 1%;Drug: QLS-101ophthalmic solution 2% | Qlaris Bio, Inc. | NULL | Recruiting | 18 Years | N/A | All | 12 | Phase 2 | United States |